AI assistant
Brainsway Ltd. Investor Presentation 2026
6701_rns_2026-05-13_1d319f9d-0263-4e99-a5e6-c2b337d67b2c.pdf
Investor Presentation
Open in viewerOpens in your device viewer
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2026
Commission File Number: 001-35165
BRAINSWAY LTD.
(Translation of registrant's name into English)
16 Hartum Street RAD Tower, 14th Floor
Har HaHotzvim
Jerusalem, 9777516, Israel
(+972-2) 582-4030
(Address and telephone number of Registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
This Form 6-K is incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on April 22, 2019 (Registration No. 333-230979) and on April 20, 2026 (Registration No. 333-295189) and the Company's Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 22, 2024 (Registration No. 333-280934) and on April 22, 2025 (Registration No. 333-286672).
EXHIBIT INDEX
| Exhibit | Title |
|---|---|
| 99.1 | Investor Deck |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BRAINSWAY LTD.
(Registrant)
Date: May 13, 2026
/s/ Hadar Levy
Hadar Levy
Chief Executive Officer
Exhibit 99.1
From an innovative technology to a fast-growing ARR company
Investor Deck
May 2026
Newbay/TASE: BWAY
Safe Harbor and Non-GAAP/IFRS Financial Measures
This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to subscribe for or acquire, any securities of the Company, nor to participate in any investment. This presentation shall not constitute advertising or be construed as commercial or promotional in nature. No representation or warranty is made as to the accuracy or completeness of this presentation. You must make your own investigation and assessment of the matters contained herein. In particular, no responsibility is assumed as to the achievement or reasonableness of any forecasts, estimates, or statements as to prospects contained or referred to in this presentation.
This presentation contains information that includes or is based on forward-looking statements within the meaning of the federal securities laws. Such statements are not guarantees of future performance. They reflect current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors include, but are not limited to: continued business impact from COVID-19; adverse economic conditions; changes in demand and pricing; manufacturing difficulties or delays; legislative and regulatory actions; changes in reimbursement; third-party payor decisions; product liability claims; U.S. healthcare reform; financial market conditions; competitive dynamics; failure to achieve sufficient market adoption; regulatory actions or delays; and our ability to realize expected operational and manufacturing efficiencies. Additional information about these and other risks is contained in our filings with the U.S. Securities and Exchange Commission. If one or more of these factors materialize, or if underlying assumptions prove incorrect, actual results may differ materially. This presentation also includes market and industry data from government and private publications and internal estimates and projections based on a number of assumptions. We undertake no obligation to update any forward-looking statement as a result of new information, future events, or otherwise.
Certain non-GAAP/IFRS financial measures are included in this presentation. These measures are presented to complement the financial information prepared in accordance with IFRS because management believes they are useful to investors. For example, Adjusted EBITDA, a non-IFRS measure, is widely used by investors and securities analysts to evaluate a company's operating performance without regard to one-time items (such as restructuring and litigation expenses) that can vary substantially from company to company. Management also uses Adjusted EBITDA with IFRS measures for planning purposes, including preparation of annual operating budgets, as a measure of operating performance. These non-GAAP/IFRS measures should be considered only as supplements to, and not superior to, financial measures prepared in accordance with IFRS. Other companies may calculate similarly titled non-GAAP/IFRS measures differently than the Company.
BrainWay
Investor Deck | May 2025
BrainsWay: Global Leader in Transcranial Magnetic Stimulation (TMS)
Installed base of >1,800 treatment centers
>7.5M individual treatments
4 FDA-cleared indications
- 2013 - Major Depressive Disorder (MDD)
- 2018 - Obsessive-Compulsive Disorder (OCD)
- 2020 - Smoking Addiction
- 2021 - Anxious Depression
September 16, 2025: FDA Clearance for Accelerated Deep TMS Protocol for MDD
Established reimbursement
BrainsWay
Investor Deck | May 2026
Q1 2026 Highlights
Strong Growth & Profitability
- Q1 2026 revenue grew 35% year-over-year to $15.5M
- Net income more than doubled to $2.3M; Adjusted EBITDA increased 117% to $2.8M
- Remaining Performance Obligations (RPO) increased 25% to approximately $75M
- Record shipment of 117 Deep TMS systems in Q1, expanding installed base to ~1,820 systems
- Cash position remained strong at $58.9M as of March 31, 2026
- Reiterated full-year 2026 guidance: revenue of $66M–$68M, operating income margin of 13%–14%, and Adjusted EBITDA of $12M–$14M
Momentum Across the Business
- Secured first insurance coverage for accelerated SWIFT™ Deep TMS protocol following FDA clearance
- Expanded payer support for nurse practitioner-administered TMS across commercial, Medicare, and government payers
- Cigna’s Evernorth Behavioral Health to eliminate prior authorization requirements for TMS Coverage, accelerating access to care
- Continued advancement of Deep TMS clinical pipeline, including AUD trial recruitment and planned FDA submission for PTSD symptoms in MDD patients in Q2 2026
- Expanded strategic investment portfolio through additional investments in Neurolief, BrainStim Health, and Axis Management Company
- Strategic Investments: 5 minority stakes
BrainWise
Adjusted EBITDA is a non-IFRS measure. See slide 34 for operating income results, the closest IFRS measure, and the reconciliation table in the Company's earnings release.
Investor Deck | May 2026
Going Forward, All About Execution
Steady Quarterly Revenue Growth
*120 Systems Shipped in Q1 / +44% Growth (Y/Y)
Profitability
75% gross margin (Q1 26)
+100% Net Income growth in Q1, 2026
$12 - $14m adjusted EBITDA guidance *
11 consecutive quarters of positive free cash flow
Strong Visibility To Future Business
Recurring revenue poised to increase:
+1820 Systems deployed
+93% customer retention rate
Remaining performance obligations (RPO) from customers under multi-year contracts:
$75M (+25% Y/Y growth)
Book-to-Bill Ratio:
1.3x
Revenue
$66-68M 2026 revenue guidance
Clean Balance Sheet 12/31/25
$59M Cash
No debt
BrainWay
*Adjusted EBITDA is a non-IFRS measure. See slide 34 for operating income results, the closest IFRS measure, and the reconciliation table in the Company's earnings release.
Investor Deck | May 2026
Business Model - Leasing
The ARR Model
+20%
YoY growth
$18.3M Recurring
$15.3M Recurring
Adj. EBITDA * Lease Sale
$6.6
7.8
2.9
2.7
9.0
9.1
10
10.5
11.4
11.5
12.6
13.5
14.5
15.5
$2
$3
$4
$5
$6
$7
$8
$9
$10
$11
$12
BrainsWay®
*Adjusted EBITDA is a non-VYO measure. See slide 34 for operating income results, the closest VYO measure, and the reconciliation table in the Company's earnings release.
Investor Deck | May 2025
Focused on ARR and Operating Leverage
Recent revenue growth: >30%
Targeted future OPEX growth: <15%
BrandWay
Adjusted EBITDA is a non-IRIS measure. See slide 34 for operating income results, the closest IRIS measure, and the reconciliation table in the Company's earnings release.
Investor Deck | May 2025
Roadmap to Growth: Key Drivers
Expanding TAM in a Massive Market
U.S Patient population
49M
Major Depressive Disorder (MDD) &
Anxious Depression,
OCD,
Smoking Addiction
FDA cleared
indications
29M
Alcohol Use
Disorder (AUD)
Future Pipeline
Indications
Alzheimer
Post-Stroke
BrandWay
Note: Other than MDD/Anxious Depression, OCD, and Smoking Addiction, the above indications are currently investigational, not available in the U.S, and not cleared by the FDA.
Investor Deck | May 2025
35 Years of Established Technology
With Demonstrated Safety and Efficacy
How it works
- An electromagnetic H-coil is placed on the scalp
- A rapid current flows through the coil
- This generates a magnetic field that induces an electric field in the brain
- The changing electric field depolarizes axons and triggers action potentials
- ~2.5× deeper penetration than standard TMS
- Deeper, broader stimulation activates more neurons
BrainWise
BrainsWay Deep TMS vs. Traditional TMS
Clear, compelling technological advantage
| Features | Traditional TMS |
|---|---|
| Depth | 0.7cm to 1.0 cm^{9} |
| Brain Volume Stimulated | Limited - 3 cm^{10} |
| Therapy Delivery | Prone to Targeting Errors |
| Structures Treated | Superficial and Focal |
| Technology Platform | RCT Data Limited to Depression |
BrainsWay
All competitors in the commercial depression space use variations of the traditional "figure-8" TMS coil design. Technological distinctions do not necessarily correlate with clinical outcomes.
Investor Deck | May 2025
BrainsWay is building the future for brain health, positioning the company to scale across multiple neurological and psychiatric conditions
| Network Neuromodulation
Only platform capable of bilateral network stimulation | Clinical Leadership
Only FDA-cleared accelerated TMS protocol (SWIFT-based)
Only FDA-cleared TMS for late-life depression (65+)
Only FDA-cleared TMS for Adolescent Depression
Only sham-controlled RCT data for OCD
Only FDA-cleared neuromodulation for smoking addiction | Care Continuum
Only neuromodulation platform spanning clinic-based treatment + At-home neuromodulation
Long-term brain health management | Provider Economics
Only system engineered to increase clinic throughput and operational efficiency
Only system cleared to deliver SWIFT-based accelerated treatment in the outpatient setting |
| --- | --- | --- | --- |
BrainsWay
Investor Deck | May 2025
Business Model - Leasing
We transformed to a winning business model
From: One time sale
To: A high-margin ARR model
BrainWay
Investor Deck | May 2025
13
Fix Lease Model & Pay Per Use
Driving $70M RPO – U.S. Only
- Removes barriers, boosts adoption
- Reduces upfront capital commitment for physicians
- Clinics pay only when they treat: faster adoption & utilization
- Provides 4-5 years contracts
- Built for today's market: solves high-rate CapEx hesitation and staffing constraints
BrainWay
Investor Deck | May 2025
55
Roadmap to Growth: Key Drivers
Strategic Partnership With Valor Equity Partners
Valor, a leading $20B equity firm behind market leaders, is now BrainsWay’s largest investor and an active partner in our scale strategy
EQUITY PARTNERS
BrainsWay
Investor Deck | May 2025
Strategic Equity Investments in Mental Health Providers
New Strategy to Accelerate Company Growth
| Strategic Initiative Led with Valor Fund | 200+
Identified Mental Health Clinics as Potential Partners |
| --- | --- |
| No Added OPEX | Each deal can potentially add 10-15 Clinics Annually |
| Each deal can deliver Significant incremental gross margin | |
BrandsWay
Investor Deck | May 2025
BrandWay
Investor Deck | May 2025
How do we partner?
Deals signed:
| Stella Mental Health
- $5M investment
- 20+ clinics
- 30,000 patients treated to date | AXIS INTEGRATED MENTAL HEALTH
- $2.3M in initial investment
- Additional $1M milestone-based investment
- Clinics in Colorado | neading
- $2.5M in initial investment
- Additional $1.5M milestone-based investment
- Clinics in Texas | radial
- Clinics in NY, Boston
- New York, South Carolina, Missouri, Tennessee, Connecticut, and California | BrainStim Health
- Up to $2.5M investment
- Clinics in Vancouver, South Surrey, Central Surrey (BC), Kingston (ON), Ottawa (ON), Perth (ON), and Halifax (NB |
| --- | --- | --- | --- | --- |
Roadmap to Growth: Key Drivers
Neurolief
Extending to Home-Use Neuromodulation
August 21, 2025: Announced Structured M&A Option
01 Explore extending deep TMS treatments with At-home* therapy - start in clinic, continue at home
02 Structured deal: $11M convertible debt; milestone tranches; call option to acquire
03 Clean P&L: no consolidation, no added OPEX
04 Bigger reach: taps ~50% telemedicine activity, clinic-prescribed home device grows TAM without extra marketing and feeds in-clinic use. Patients can go directly to their primary care physician (PCP)
BrainoWay
Investor Deck | September 2025
International Growth Opportunities
Existing Partnership:
- Europe – 37M Depression Patients
- India – 57M Depression Patients
- China – 71M Depression Patients
- Japan – 6M Depression Patients
- Australia – 1.3M Depression Patients
BrainWay
Investor Deck | May 2025
Roadmap to Growth: Key Drivers
Upside Potential: Deep TMS 360™ Research*
Overview
- Potential Novel solution being explored for shorter treatment, better efficacy, and possible new indications
- Enables activation of greater numbers of neurons in the brain than currently available forms of TMS
May be uniquely suited for older adults with neurodegenerative conditions and reduced neuroplasticity
Today's TMS: Single coil
- Neurons aligned parallel to coil's electrical field are more likely to be stimulated
- As a result, only a fraction of neurons in the targeted brain region are actually impacted
- Deep TMS 360: Rotational Field system has 2 perpendicular orthogonal TMS coils
- 2 coils are operated with short time lag (milliseconds) in order to induce a circularly rotating electrical field
- Results in uniform stimulation of neurons oriented across a wide range of directions
Deep TMS 360 Clinical Plans
- Launched Alcohol use disorder trial in Q3 2025
- Launched study on post-stroke rehabilitation in LH 2024
- Plans to initiate feasibility studies on various neurology indications (dementia, Parkinson's, Alzheimer's)
BrainWay
*Deep TMS 360 is being investigated for clinical trial research and is not commercially available. This slide is forward-looking only.
Investor Deck | May 2025
Accelerated Treatment
From 6 weeks
→ To 6 days*
- Accelerated Deep TMS protocol: 1,800 iTBS pulses at 110% of MT using the H1 coil
- 30 total sessions
- Flexible scheduling - days can be non-consecutive
Accelerated Trial Outcomes
(n=104 patients enrolled, 89 completers mITT outcomes displayed)
BrainWay
*Acute phase, before required maintenance sessions
Investor Deck | May 2025
Indications
Smoking Addiction
28.3M
U.S Adult Smokers
$2B/year
nearly spent by smokers on Quitting
85%
of them don't succeed
With Brainsway:
~1 out of 3
patients quit for 4 weeks
~67%
of 6-week completers remained non-smokers for +3 months
1st and Only TMS Addiction Clearance
BrainsWay
Investor Deck | May 2025
PTSD New Article (2024)*
Real-world evidence showing significant reductions in comorbid PTSD symptoms in MDD patients for up to 6 months after treatment
99 patients in VA clinic
H1-coil, FDA-approved depression protocol
3-week taper (maintenance)
Significant reductions in PTSD symptoms, depression, and suicidal thoughts observed immediately after treatment, at 3 months, and at 6 months
- Impressive outcomes of response and remission
Hickson et al., Psychiat Res. 2024
BrainWay
*Deep TMS is not FDA-cleared for PTSD. Data collection efforts underway.
Investor Deck | May 2025
Depression Clinical Efficacy: Demonstrated Safety and Efficacy
After 30 sessions
Response
Remission
- Durability in TMS is >1 Year in ~50% of Responders
-
A published abstract of 200 patients from a single BrainsWay site showed average durability of 860 days
-
~2 in 3 patients achieved remission with Deep TMS
- 1,351 MDD patients who received at least 20 Deep TMS sessions
- No systemic side effects
BrainsWay
Investor Deck | May 2025
OCD Clinical Efficacy
After 29 sessions
57.9 %
Response
- 219 patients across 22 centers
- Sustained response achieved in ~20 sessions
- No systemic side effects
87.0 %
Durability of 1+ Years
- n = 60 patients (from pivotal and post-market studies)
- Durability = time from end of Deep TMS course to change in ongoing treatment
Investor Deck | May 2026
BrainWley
Strong Economic and Clinical Incentive for Adopters
Robust Reimbursement Coverage Drives Compelling Clinician ROI
Reimbursement
3 well-established CPT codes
250M+ covered for Depression
Medicare & major commercial insurers in all 50 states
100M+ covered for OCD
New policies – Cigna, Palmetto, Centene, HCSC, Tricare
BrainWley
Investor Deck | May 2025
Most Extensive and Broadest TMS Intellectual Property
Encompassing Core Technology and Applications
Patent Portfolio
Issued Patents or Allowed Applications
Key Portfolio Coverage Areas
- Deep TMS™ Coils
- Multi-Channel TMS
- Rotational Field Deep TMS
- Closed Loop TMS/EEG
BrainWay®
Investor Deck | May 2025
Upcoming Planned Milestones and Catalysts*
12 Month
Near-Term
- FDA accelerated protocol clearance
- Recruitment for New AUD trial
- FDA adolescent clearance
- First 5 minority stake deployments
12-36 Month
Mid-Term
- FDA Comorbid PTSD application
- Neurolief Home use device launch
- Full enterprise rollout (10+ new accounts)
- Broader coil adoption
- New payer coverage wins
36 + Month
Long-Term
- Neurology portfolio
- BrainsWay 360 global launch
- Selective global expansion
*Milestones on this slide are forward looking in nature. See cover slide.
Investor Deck | May 2025
Summary Highlights
- Category Leader – Only Deep TMS platform with 4 FDA cleared indications
- Expanding TAM – New indications, Neurolief at-home entry, international scale
- Recurring Revenue Model / PPU – multi-year agreement
- High Visibility - $75M Remaining Performance Obligations (RPO)
- Strong Profitability – 11 straight quarters of positive free cash flow
- Backed to Scale – $59M cash; strategic partner Valor supports continued expansion
BrainWay®
Investor Deck | May 2025
Strong Financial Momentum.
Brain&Way
Adjusted EBITDA is a non-IFRS measure. See slide 34 for operating income results, the closest IFRS measure, and the reconciliation table in the Company's earnings release.
Investor Deck | May 2025
Q1 2026 VS. Q1 2025
| Actual | Actual | Variance | ||
|---|---|---|---|---|
| Q1 2026 | Q1 2025 | $ | % | |
| USD in thousands | ||||
| Revenues | 15,531 | 11,536 | 3,995 | 35% |
| Cost of Revenues | 3,856 | 2,926 | 930 | 32% |
| Gross profit | 11,675 | 8,610 | 3,065 | 36% |
| Gross Margin | 75% | 75% | ||
| Research and Development expenses | 2,881 | 2,332 | 549 | 24% |
| Selling and Marketing expenses | 4,930 | 4,162 | 768 | 18% |
| General and Administrative expenses | 1,859 | 1,540 | 319 | 21% |
| Total Operating expenses | 9,670 | 8,034 | 1,636 | 20% |
| Operating Income | 2,005 | 576 | 1,429 | 248% |
| Finance income, net | 405 | 688 | (283) | -41% |
| Income Tax expense | 120 | 157 | (37) | -24% |
| Net Income | 2,290 | 1,107 | 1,183 | 107% |
| Adjusted EBITDA | 2,812 | 1,295 | 1,517 | 117% |
| Basic net income per share | 0.06 | 0.03 | 0.03 | 100% |
| Diluted net income per share | 0.06 | 0.02 | 0.04 | 200% |
Inventor Deck | May 2026
Q1 2026 Balance Sheet
| USD in thousands | As of March 31, 2026 | As of December 31, 2025 | As of March 31, 2025 |
|---|---|---|---|
| ASSETS | |||
| Cash and cash equivalents | 58,636 | 67,700 | 71,601 |
| Restricted cash | 251 | 251 | 271 |
| Trade receivables, net | 7,530 | 4,111 | 6,954 |
| Inventory | 7,078 | 6,523 | 4,680 |
| Other current financial assets | 1,138 | 1,432 | - |
| Other current assets | 3,993 | 3,807 | 1,150 |
| Total Current Assets | 78,626 | 83,824 | 84,656 |
| Non-Current Assets | 38,372 | 29,367 | 15,542 |
| Total Assets | 116,998 | 113,191 | 100,198 |
| LIABILITIES AND EQUITY | |||
| Current Liabilities | 23,555 | 22,495 | 16,846 |
| Non-Current Liabilities | 17,646 | 17,533 | 19,602 |
| Equity | 75,797 | 73,163 | 63,750 |
| Total Liabilities and Equity | 116,998 | 113,191 | 100,198 |
Inventor Deck | May 2026
BrainWay
9
BrainsWay Leadership Team
Successful, Experienced Medical Device Professionals - Decades of Results
Hadar Levy
Chief Executive Officer
25+ Years Med Device
Ido Marom
Chief Financial Officer
20+ Years Finance
Dr. Gilead Moiseyev
Chief Technology Officer
20+ Years Med Device Dev
Naomi Rosenfeld
Chief Marketing Officer
20+ Years global Marketing
Dr. Colleen Hanlon
Vice President - Medical Affairs
15+ Years Brain Stim Research
Nurit Tsur Lev
Vice President – OUS Sales
20+ Years Biomed Sales
Michael Cohen
Vice President - US Sales
15+ Years Med Device Sales
Moria Ben Soussan
Vice President - R&D
15+ Years Med Device Dev
Dor Hagai
Vice President – Operations
10+ Years Supply Chain & Ops
Monachem Klein
Vice President – General Counsel
15+ Years Med Device
BrainsWay
Investor Deck | May 2026
References
- BrainxWay Data on File
- The Notional Institute of Mental Health: nimh.nih.gov
- Kessler RC, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey Br J Psychiatry Suppl. 1996
- Trivedi MH et al. STARD Study Team (2006), Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: implications for clinical practice. Am J Psychiatry. 2006 Jan; 163(1):28-40.
- Greist JH. The comparative effectiveness of treatments for obsessive-compulsive disorder. Bull Menninger Clin. 1998;62(4, suppl 1A):A65–A81
- Marks I. Behavior therapy for obsessive-compulsive disorder: a decade of progress. Can J Psychiatry. 1997;42:1021–1027
- Bailenger JC. Current treatments of the anxiety disorders in adults. Biol Psychiatry. 1999;46: 1579–1594
- Lawson McLean A. Publication trends in transcranial magnetic stimulation: a 30-year panorama. Brain Stimul. 2019 May-Jun;12(3): 619-627
- BrainxWay Data on File; Depth, measured in phantom head, is from cortical surface toward brain center for which E-field >=100V/m for calibrated stimulator output. If measuring from scalp surface, an additional 1.5 cm should be added; See also, Guadagnin, V., et. al., 2016. Deep Transcranial Magnetic Stimulation: Modeling of Different Coil Configurations. 63, 1543–1550.
- Fieschi, S., et. al., 2016. Modelling of the Electric Field Distribution in Deep Transcranial Magnetic Stimulation. 2016
- Company estimates, references. S RM adult MDD patients with insurance coverage and assumes 33 sessions per patient with an average session price of $70; Oppenheimer Research Report, 08/24/2020
- Tendler, A, et al. Deep TMS I41 Coil treatment for depression: Results from a large post marketing data analysis. Psychiatry Research. Vol 324, June 2023, 115179
- Senova S, et al. Durability of antidepressant response to repetitive transcranial magnetic stimulation: Systematic review and meta-analysis. Brain Stimulation 12 (2019) 119e128
- Gersner P, et al. What is the durability of Deep TMS for Major Depressive Disorder. Brain Stimulation 13 (2020) 1842-1862
- Roth F, et al. Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sites. J Psychiatr Res. 2020 Nov 4;S0022 3956(20)31065-7
- Harmelsch T et al. Long-term outcomes of a course of deep TMS for treatment-resistant OCD. Brain Stimulation 15 (2022) 226e228
- https://www.cdc.gov/tobacco/data_statistics/fact_sheets/cessation/smoking-cessation-fast-facts/index.html. Data as of 2018 for U.S. adults.
- EY Parthenon Analysis 2018
https://www.smokefreeworld.org/sites/default/files/ey-p_smoking_cessation_landscape_analysis_key_findings.pdf - Zangen A et al. Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. World Psychiatry. 2021 Oct;20(3):397-404
- https://worldpopulationreview.com/country-rankings/depression-rates-by-country
BrainxWay
Investor Deck | May 2026